The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 26, 2022
Filed:
Feb. 09, 2018
Fred Hutchinson Cancer Center, Seattle, WA (US);
University of Washington, Seattle, WA (US);
Bloodworks Northwest, Seattle, WA (US);
W. Conrad Liles, Seattle, WA (US);
Cameron J. Turtle, Seattle, WA (US);
David G. Maloney, Issaquah, WA (US);
Stanley R. Riddell, Sammamish, WA (US);
Mark M. Wurfel, Seattle, WA (US);
Jose Lopez, Seattle, WA (US);
Dominic Chung, Bellevue, WA (US);
Junmei Chen, Seattle, WA (US);
Fred Hutchinson Cancer Center, Seattle, WA (US);
University of Washington, Seattle, WA (US);
Bloodworks Northwest, Seattle, WA (US);
Abstract
The instant disclosure provides biomarkers and methods for identifying subjects at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both after adoptive immunotherapy to guide preemptive intervention, modified therapy, or the like. For example, adverse event biomarkers may be measured in a subject before pre-conditioning chemotherapy, before immunotherapy (e.g., adoptive immunotherapy infusion comprising a chimeric antigen receptor (CAR) modified T cell), or shortly after pre-conditioning chemotherapy and/or immunotherapy. Exemplary biomarkers include temperature, cytokine levels and endothelial activation biomarkers, such as angiopoietin 2, von Willebrand factor (vWF), ratio of angiopoietin 2 to angiopoietin 1, and ratio of ADAMTS13 to vWF. Also provided are methods of treating subjects identified as at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both to minimize such potential adverse events.